SecBot SecBot
8-K ·Filed Apr 7, 2026

NUVL

Nuvalent, Inc.
BULLISH
Impact 7/10
Horizonmonths Processed7mo ago SEC0001861560-26-000003
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish

Traders should monitor FDA review timelines and potential upcoming catalysts, such as priority review designation or PDUFA date announcements. This NDA submission increases the near-term value inflection potential for NUVL stock.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$102.25
T+0 close · Apr 7, 2026 · via day close
Latest settled
+21.01%
T+60 · $123.73
Vs SPY
+7.74%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 7 $102.25entry
  2. T+1 · 7mo ago +2.73%α +0.19% · $105.04
  3. T+5 · 7mo ago +2.71%α −2.62% · $105.02
  4. T+20 · 7mo ago +0.36%α −9.42% · $102.62
  5. T+60 · 5mo ago +21.01%α +7.74% · $123.73
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Nuvalent, Inc. announced the submission of its New Drug Application (NDA) to the U.S. FDA for neladalkib, a treatment for tyrosine kinase inhibitor pre-treated advanced ALK-positive non-small cell lung cancer. This is a key regulatory milestone in the company's oncology pipeline.

Key Facts

  • Nuvalent submitted a New Drug Application (NDA) to the FDA for neladalkib.
  • The drug candidate targets advanced ALK-positive non-small cell lung cancer in patients previously treated with tyrosine kinase inhibitors.
  • The announcement represents a significant advancement in the company's clinical development program.
  • No financial figures or timelines for FDA decision were disclosed in the filing.

Financial Impact

Potential future revenue from neladalkib if approved; no specific figures disclosed.

revenuedrug pipeline valuemarket sentiment

Risk Factors

  • FDA may not approve neladalkib or may require additional data.
  • Competition from existing and emerging ALK inhibitors could impact market adoption.
  • As a clinical-stage biotech, Nuvalent remains subject to high regulatory and development risk.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001861560-26-000003
Document: 0001861560-26-000003-index-headers.html0001861560-26-000003
Document: 0001861560-26-000003-index.html0001861560-26-000003
Document: 0001861560-26-000003.txt0001861560-26-000003

US Market Status

Market Closed · Opens Wed (10h 38m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 7, 2026